Foligraf 75IU Injection contains recombinant follicle stimulating hormone (FSH) at a dose of 75IU, a vital hormone used primarily in assisted reproductive technologies and fertility treatments. This medication stimulates the growth and maturation of ovarian follicles in women undergoing controlled ovarian hyperstimulation as part of in vitro fertilization (IVF) or other assisted reproductive procedures. By promoting follicular development, Foligraf helps increase the chances of successful ovulation and conception. It is also used in cases of anovulation or oligo-ovulation where endogenous FSH levels are insufficient. The recombinant nature of the hormone ensures high purity and consistency, reducing the risk of allergic reactions compared to urinary-derived FSH products. Foligraf is administered via subcutaneous or intramuscular injection, with dosage and duration tailored by a healthcare professional based on individual patient response and treatment protocols. Common side effects may include mild injection site reactions, headache, or abdominal discomfort, but serious adverse effects are rare when used as directed. Patients should be monitored regularly through ultrasound and hormone level assessments to optimize treatment outcomes and minimize risks such as ovarian hyperstimulation syndrome (OHSS). Foligraf 75IU Injection is a critical component in modern fertility management, offering hope to individuals and couples facing infertility challenges.